The Goldman Sachs Group Upgrades BioNTech (NASDAQ:BNTX) to Buy

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX - Free Report) from a neutral rating to a buy rating in a research note released on Friday morning, Marketbeat reports. The firm currently has $137.00 price objective on the stock, up from their prior price objective of $90.00.

A number of other research analysts have also recently commented on the company. Bank of America raised their target price on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, September 16th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of BioNTech from $95.00 to $150.00 and gave the company a "buy" rating in a report on Thursday, September 19th. HSBC increased their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Jefferies Financial Group raised shares of BioNTech from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Finally, UBS Group upped their price objective on shares of BioNTech from $97.00 to $131.00 and gave the stock a "neutral" rating in a report on Wednesday, September 18th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, BioNTech currently has a consensus rating of "Moderate Buy" and a consensus price target of $137.54.

BioNTech Trading Up 2.6 %

Shares of BNTX stock traded up $2.76 during mid-day trading on Friday, reaching $110.64. The stock had a trading volume of 1,237,368 shares, compared to its average volume of 785,258. The firm has a market capitalization of $26.31 billion, a PE ratio of -52.69 and a beta of 0.26. The stock's 50-day moving average price is $111.85 and its two-hundred day moving average price is $96.55. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.34% and a negative net margin of 15.16%. The firm's revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 earnings per share. Equities analysts expect that BioNTech will post -2.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BNTX. Candriam S.C.A. lifted its position in BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock valued at $46,526,000 after purchasing an additional 418,695 shares during the period. Point72 Asset Management L.P. raised its stake in BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock valued at $37,103,000 after buying an additional 341,311 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in shares of BioNTech by 457.9% during the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company's stock valued at $25,900,000 after buying an additional 178,981 shares during the period. abrdn plc boosted its stake in shares of BioNTech by 334.4% in the 3rd quarter. abrdn plc now owns 225,992 shares of the company's stock worth $26,841,000 after buying an additional 173,969 shares during the last quarter. Finally, Lodestone Wealth Management LLC bought a new stake in shares of BioNTech in the third quarter worth $8,373,000. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.